Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas

Exclusion Criteria

• •Patients receiving cancer therapy within 3 weeks prior to Cycle1 Day1 (C1D1).
• •Patients with active Hepatitis B virus (HBV), Hepatitis C virus (HCV) or Human immune deficiency virus (HIV) infection
• •Patients who received Allo-Stem cell Transplantation(Allo-SCT) within 12 months.
• •Patients with graft versus-host disease (GVHD)
• •Subjects who have received drugs that directly or indirectly inhibit calcineurin or Nuclear Factor of activated T cells (NFAT) activity .
• •Patient with symptomatic, or history of documented congestive heart failure (NY Heart Association functional classification III-IV);
• •Patient with Frederica's (QTcF) formulas (QTcF) ≥450 msec;
• •Patient with angina not well-controlled by medication;
• •Women who are pregnant or lactating.